针对丝裂原活化蛋白激酶信号通路的胃癌靶向治疗研究进展

Research progress on targeted therapy for gastric cancer with mitogen-activated protein kinase signaling pathway

胃癌在全世界范围内都具有较高的发病率和死亡率,是威胁人类健康的一大难题。靶向治疗药物的出现,使中晚期胃癌治疗得到突破,延长了无数胃癌患者的生存期,但耐药和毒性作用等问题仍然存在,因此需要寻找更加安全可靠的靶向药物。近年来,丝裂原活化蛋白激酶(mitogen-activatedprotein kinase,MAPK)信号通路被发现与胃癌的发生发展密切相关,能够影响胃癌细胞的增殖、侵袭、凋亡等,也有许多影响MAPK信号通路的药物被相继发现。本文通过查阅相关文献,对针对MAPK信号通路的胃癌靶向治疗药物的研究作一综述,以期为胃癌的靶向治疗提供新的思路。

Gastric cancer has a high morbidity and mortality rate all over the world and is a major problem threatening human health.The emergence of targeted therapeutic drugs has made a breakthrough in the treatment of middle and advanced gastric cancer and extended the survival time of countless gastric cancer patients.However,drug resistance and toxic effects still exist,so it is necessary to find safer and more reliable targeted drugs.In recent years,mitogen-activated protein kinase(MAPK)signaling pathway has been found to be closely related to the occurrence and development of gastric cancer,which can affect the proliferation,invasion and apoptosis of gastric cancer cells.Moreover,many drugs affecting MAPK signaling pathway have been discovered in succession.By referring to relevant documents,this article reviews the researches of targeted therapeutic drugs for gastric cancer targeting MAPK signaling pathway,hoping to provide a new idea for the research of targeted therapy for gastric cancer.